Mediwound Ltd Expected to Post Q3 2017 Earnings of ($0.19) Per Share (MDWD)
Mediwound Ltd (NASDAQ:MDWD) – Stock analysts at SunTrust Banks raised their Q3 2017 EPS estimates for Mediwound in a research note issued on Monday. SunTrust Banks analyst B. Nudell now forecasts that the biopharmaceutical company will earn ($0.19) per share for the quarter, up from their prior forecast of ($0.20). SunTrust Banks also issued estimates for Mediwound’s Q4 2017 earnings at ($0.20) EPS.
Mediwound (NASDAQ:MDWD) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. Mediwound had a negative net margin of 1,776.06% and a negative return on equity of 148.23%. The firm had revenue of $0.54 million during the quarter, compared to analyst estimates of $0.56 million. During the same period in the prior year, the business earned ($0.17) EPS. The business’s revenue for the quarter was up 112.6% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/05/11/mediwound-ltd-expected-to-post-q3-2017-earnings-of-0-19-per-share-mdwd.html.
MDWD has been the topic of a number of other research reports. Zacks Investment Research lowered shares of Mediwound from a “buy” rating to a “hold” rating in a report on Wednesday, January 11th. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $10.00 target price on shares of Mediwound in a report on Wednesday, February 1st. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $10.75.
Shares of Mediwound (NASDAQ:MDWD) opened at 5.80 on Thursday. The firm’s market cap is $127.19 million. The firm has a 50 day moving average price of $6.42 and a 200 day moving average price of $5.80. Mediwound has a 1-year low of $4.25 and a 1-year high of $8.58.
Large investors have recently bought and sold shares of the company. Broadfin Capital LLC raised its stake in Mediwound by 19.2% in the fourth quarter. Broadfin Capital LLC now owns 633,102 shares of the biopharmaceutical company’s stock worth $2,899,000 after buying an additional 102,117 shares in the last quarter. Citadel Advisors LLC raised its stake in Mediwound by 4.5% in the third quarter. Citadel Advisors LLC now owns 33,622 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 1,456 shares in the last quarter. Renaissance Technologies LLC raised its stake in Mediwound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 7,900 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in Mediwound during the third quarter worth $1,740,000. Finally, Wells Fargo & Company MN raised its stake in Mediwound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares in the last quarter. Institutional investors own 27.49% of the company’s stock.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with MarketBeat.com's FREE daily email newsletter.